<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446523</url>
  </required_header>
  <id_info>
    <org_study_id>endotoxins in MHE</org_study_id>
    <nct_id>NCT01446523</nct_id>
  </id_info>
  <brief_title>S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE</brief_title>
  <acronym>endtxninHE</acronym>
  <official_title>Serum Endotoxins, Inflammatory Mediators and MR Spectroscopy Before and After Treatment in Minimal Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Govind Ballabh Pant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Govind Ballabh Pant Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine S.endotoxins , inflammatory mediators and Magnetic&#xD;
      Resonance Spectroscopy (MRS) before and after treatment in patients of cirrhosis and minimal&#xD;
      hepatic encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients of cirrhosis with Minimal Hepatic Encephalopathy (MHE) who fulfills the inclusion&#xD;
      &amp; exclusion criteria will be the part of study. Study patients will be divided in to two&#xD;
      groups ( n=30 in each group).&#xD;
&#xD;
      Group L patients will receive lactulose therapy while Group NL will receive placebo. After 3&#xD;
      months , S.endotoxins , inflammatory mediators and MRS will be repeated in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of minimal hepatic encephalopathy</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between inflammatory mediators and grades of encephalopathy</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
    <description>To measure values of inflammatory mediators in different grades of encephalopathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group L receives lactulose Group NL receives placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group NL receives placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Syrup, 30 ml BD for 3 months in Gr. NL</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Syrup 30 ml BD for 12 weeks</description>
    <arm_group_label>Lactulose</arm_group_label>
    <other_name>Duphalac , Looz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Cirrhosis (Age 15 yr -70 yr )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent history of gastrointestinal bleed in last 6 weeks&#xD;
&#xD;
          -  Active ongoing infection&#xD;
&#xD;
          -  Creatinine &gt;1.5mg%&#xD;
&#xD;
          -  Electrolyte impairment. (S. Sodium &lt; 130 meq/L, S. Potassium 3.5 meq/L or &gt;5.0meq/L)&#xD;
&#xD;
          -  H/O use of psychotropic drugs in last 6 weeks&#xD;
&#xD;
          -  Recent alcohol use (&lt; 6 week )&#xD;
&#xD;
          -  H/O TIPS or shunt surgery.&#xD;
&#xD;
          -  Hepatocellular Carcinoma&#xD;
&#xD;
          -  Severe comorbidity as Congestive Heart Failure, Pulmonary disease, Neurological and&#xD;
             Psychiatric problems impairing quality of life&#xD;
&#xD;
          -  Poor vision precluding neuropsychological assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barjesh c Sharma, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>GB Pant Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Sharma</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Govind Ballabh Pant Hospital</investigator_affiliation>
    <investigator_full_name>Barjesh Chander Sharma</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endotoxins HE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

